Radiopharmaceuticals company Navidea Biopharmaceuticals (NYSE Amex:NAVB) has opened a Boston-area commercialization office.Employees at Navidea’s new Andover, Massachusetts office will focus much of their attention on the expected launch later this year of drug candidate Lymphoseek, a targeting agent used by surgeons to identify lymph nodes in patients with breast cancer or melanoma and to indicate [...]

A public ethics group is calling on the U.S. Securities and Exchange Commission to investigate a hedge fund manager who made headlines last year for being an outspoken short seller of Navidea Bioscience‘s (NASDAQ:NAVB) stock.Citizens for Responsibility and Ethics in Washington (CREW) said it’s looking into whether investors such as Martin Shkreli of MSMB Capital [...]

Radiopharmaceuticals developer Navidea Biopharmaceuticals (NYSE Amex:NAVB) has signed a deal that gives it the option to license a Parkinson’s disease imaging agent from Alseres Pharmaceuticals.Under the terms of the deal, Navidea (formerly known as Neoprobe) pays Alseres $500,000 for exclusive rights during a six-month period when it can perform due diligence and negotiate a definitive [...]

Radiopharmaceuticals developer Navidea Biopharmaceuticals (NYSE Amex:NAVB) has secured up to $10 million in debt financing that strengthens the company’s balance sheet and could help with future acquisitions or licensing deals.The debt funding comes from Hercules Technology Growth Capital (Nasdaq:HTGC), a financial firm that provides loans to technology companies, according to a statement from Dublin, Ohio-based [...]

Neoprobe‘s (NYSE Amex:NEOP) newly licensed drug candidate that could aid in the diagnosis of Alzheimer’s disease has a potential worldwide market of more than $1 billion, a company official said.Further, Dublin, Ohio-based Neoprobe expects to secure a “significant portion” of that market if and when the drug is commercialized, said Thomas Tulip, Neoprobe’s chief business [...]

Neoprobe (NYSE Amex:NEOP) has licensed from AstraZeneca (NYSE:AZN) the worldwide rights to an imaging drug candidate that could aid in the diagnosis of Alzheimer’s disease.Neoprobe said it plans to begin a phase 3 clinical program involving the radiopharmaceutical imaging agent, called AZD4694, in early 2013, according to a statement from the Dublin, Ohio-based company.The drug [...]

Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) has a new name: Navidea Biopharmaceuticals.The Dublin, Ohio company chose the new moniker because it represents Neoprobe’s commitment to “NAVigating IDEAs” that translate innovation into commercial products that improve patient care, according to a statement.The name change became necessary earlier this year when Neoprobe sold off its radiation detection [...]

After Neoprobe (NYSE Amex:NEOP) sold off its top revenue-producing asset (along with its name) to transform itself into a pure-play radiopharmaceutical company, it had to find itself a new brand.Now, the company is on the verge of announcing that brand, CEO Mark Pykett said in the Dublin, Ohio company’s third-quarter earnings release.“In the coming weeks, [...]

Life science current events this week include Neoprobe gets Lymphoseek’s New Drug Application accepted by FDA but hedge fund critic still predicts it will not win approval, and Cleveland Clinic’s wellness chief Michael Roizen’s new venture.

After remaining silent on Neoprobe (NYSE Amex:NEOP) the last few months, the cancer diagnostics company’s most outspoken critic and short seller has found himself back in the spotlight after the FDA accepted for review a drug application from the company.And that critic — Martin Shkreli of New York hedge fund MSMB Capital — is still [...]